Medical related covid-19 treatment, covid-19 detection and other sectors rose against the trend today (14th), and concept stocks set off a trading tide. After hours, many soaring stocks disclosed stock price changes one after another.
On March 14, China Meheco Group Co.Ltd(600056) issued a risk warning announcement. According to the announcement, the company’s shares have risen by the limit seven times in nine trading days from March 2, 2022 to March 14, 2022, with a cumulative increase of 107.39%, and have touched the abnormal fluctuation of stock trading price three times. As of the closing date of March 14, 2022, the median price earnings ratio (TTM) of the pharmaceutical circulation industry was 14.87, and the company’s price earnings ratio (TTM) was 27.08, which was significantly higher than that of the same industry. In view of the large fluctuation range of the company’s share price, please pay attention to the transaction risk of the secondary market, make rational decisions and invest prudently.
The announcement also gives risk tips on the cooperation between China Meheco Group Co.Ltd(600056) and Pfizer:
China Meheco Group Co.Ltd(600056) signed an agreement with Pfizer on March 9, 2022 and issued Lin 2022007 announcement on signing an agreement with Pfizer on March 10. The company will be responsible for the commercial operation of Pfizer Inc COVID-19 virus treatment PAXLOVID (hereinafter referred to as “product”) in the Chinese mainland market during the agreement period (2022).
On February 11, 2022, the State Drug Administration approved the import registration of the product with conditions. This product is a prescription drug, has not entered the national medical insurance and covid-19 pneumonia diagnosis and treatment plan of China at present, the final use and sales of are affected by epidemic prevention and control and other factors, there is great uncertainty, and it is estimated that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance
On the disk, on the 14th, China Meheco Group Co.Ltd(600056) once again raised the limit word by word harvest the triple board. As of the closing on the 14th, the company’s share price rose 9.99% to close at 23.02 yuan / share, with a total market value of 24.6 billion yuan
On March 14, Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) issued an announcement on abnormal fluctuations in stock trading. According to the announcement, Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) shares have been traded for three consecutive trading days (March 10, March 11 and March 14, 2022) the cumulative deviation from the increase of closing price has reached 30% , which belongs to abnormal fluctuation of stock trading according to relevant regulations.
After the company’s self-examination and sent a letter to ask the controlling shareholder and actual controller, as of the disclosure date of this announcement, there are no major matters that should be disclosed but not disclosed
The announcement also clarified media reports, market rumors and hot spot concepts:
Recently, the company paid attention to the online report that “yanyeyi covid-19 drug ensitrelvir intermediate supplier Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) , yanyeyi drug intermediates are mainly polypeptides, while Nuotai is the main manufacturer of polypeptide intermediates and APIs, and the only listed company with yanyeyi covid-19 drug intermediates in the public data”. For the above report, the company clarifies as follows:
\u3000\u30001. At present, the company has carried out the research and development of intermediates mentioned in the report and has the supply capacity of small batches in the research and development laboratory, but has not yet carried out commercial production;
\u3000\u30002. As of the date of this announcement, the company has not provided the above intermediates to yanyeyi pharmaceutical company of Japan.
On the disk, on the 14th, Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) shares rose by the limit. As of today’s (14th) closing, Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) shares rose by 20% to close at 41.28 yuan / share, with a total market value of 8.8 billion yuan.
On March 14, Shenzhen Everbest Machinery Industry Co.Ltd(002980) issued an announcement on abnormal fluctuations in stock trading. According to the announcement, Shenzhen Everbest Machinery Industry Co.Ltd(002980) stock’s closing price rose by 20% on March 11 and March 14, 2022 consecutive trading days according to relevant regulations, it belongs to abnormal fluctuation of stock trading.
After the company’s self-examination and sent a letter to ask the controlling shareholder and actual controller, as of March 14, 2022, there are no major matters that should be disclosed but not disclosed
As of the announcement date, the company’s New Coronavirus antigen rapid test kit has not yet obtained the certificate of registration issued by China’s drug administration. has obtained self testing kit for New Coronavirus antigen approved by CE, which is used by European Union and is used by medical professionals familiar with rapid antigen detection or trained with regularity. is not a self testing product . The future market demand, market expansion, market competition and final sales of reagent products are uncertain.
On the disk, on the 14th, Shenzhen Everbest Machinery Industry Co.Ltd(002980) shares rose by the limit. As of the closing on the 14th, Shenzhen Everbest Machinery Industry Co.Ltd(002980) shares rose by 10.01% to close at 37.37 yuan / share, with a total market value of 4.983 billion.
In addition to the above companies, Nanjing Vazyme Biotech Co.Ltd(688105) also issued a related announcement today, saying that the sales of New Coronavirus antigen detection kit can not predict the sustained performance of the company’s future performance. Shenzhen Bioeasy Biotechnology Co.Ltd(300942) said that the covid-19 virus antigen detection products of the company and its wholly-owned subsidiary xiupu biology had not obtained the medical device registration certificate Thalys Medical Technology Group Corporation(603716) also said that the New Coronavirus antigen detection kit developed by the company has been applied but has not yet obtained the medical device registration certificate issued by the China National Drug Administration.
